Dr. Peter Gibson, MD
The Alfred and Monash University
In patients with irritable bowel syndrome, the manipulation of functional aspects of gut microbiota by reducing important dietary fermentable substrates (FODMAPs), rather than by changing its microbial composition, is highly effective in alleviating symptoms in the majority of patients.
Peter Gibson is Professor and Director of Gastroenterology at The Alfred and Monash University, having previously been Professor of Medicine at Eastern Health and Head of the Eastern Health Clinical School. He is a Past-President of the Gastroenterological Society of Australia. From a background of research in epithelial cell biology, he now directs a large program of translational research, and has active clinical interests in inflammatory bowel disease, coeliac disease and irritable bowel syndrome. Major foci of his work include the use of diet to control gut symptoms and influence outcomes in chronic intestinal conditions, and the optimisation of clinical management in inflammatory bowel disease. He has published widely on these topics. He was awarded the Distinguished Research Prize by the Gastroenterological Society of Australia in 2010.
Gibson, P. (2017a). History of the low FODMAP diet. Journal of Gastroenterology and Hepatology, 32, pp.5-7.
Gibson, P. (2017b). The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy? Journal of Gastroenterology and Hepatology, 32, pp.32-35.
Gibson, P. (2017c). Use of the low-FODMAP diet in inflammatory bowel disease. Journal of Gastroenterology and Hepatology, 32, pp.40-42.
How & When to Use the FODMAP Diet
The FODMAP Diet has been used since 2004 to reduce symptoms of Irritable Bowel Syndrome (IBS) and other functional bowel disorders. Learn how and when to use the FODMAP Diet – directly from the researcher who developed the diet.
History of the FODMAP Diet
The FODMAP Diet has been a savior to many with functional bowel disorders. Learn how this diet was developed and gain some insight into future treatments of functional bowel disorders.